AKT1 polymorphisms and survival of early stage non-small cell lung cancer

Journal of Surgical Oncology

Volumn 105, Issue 2, 2012, Pages 167-174

  Kim, Min Jung ^a   Kang, Hyo Gyoung ^a   Lee, Shin Yup ^b   Jeon, Hyo Sung ^a   Lee, Won Kee ^a   Park, Ji Young ^b   Lee, Eung Bae ^b   Lee, Jae Hee ^b   Cha, Sung Ick ^b   Kim, Dong Sun ^a   Kim, Chang Ho ^b   Kam, Sin ^a   Jung, Tae Hoon ^b   Park, Jae Yong ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

Author keywords

AKT1; non small cell lung cancer; polymorphisms; survival

Indexed keywords

PROTEIN KINASE B; PROTEIN KINASE B ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SURVIVAL RATE;

EID: 84855347923     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22071     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
2. Miller YE,: Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol 2005; 33: 216-223. (Pubitemid 41254287)
3. Arrigada R, Bergman B, Dunant A, et al.: Cisplatin-based adjuvant chemotherapy for completely resected non-small cell lung cancer. N Eng J Med 2004; 350: 351-360. (Pubitemid 38101630)
4. Singhal S, Vachani A, Antin-Ozerkis D, et al.: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review. Clin Cancer Res 2005; 11: 3974-3986. (Pubitemid 40791561)
5. Zhang X, Miao X, Sun T, et al.: Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005; 42: 479-484. (Pubitemid 40847235)
6. MacPherson G, Healey CS, Teare MD, et al.: Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 2004; 24: 1866-1869. (Pubitemid 40081324)
7. Park JY, Park JM, Jang JS, et al.: Caspase 9 promoter polymorphisms and risk of primary lung cancer. Human Mol Genet 2006; 15: 1963-1971. (Pubitemid 43983270)
8. Zhou W, Gurubhagavatula S, Liu G, et al.: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939-4943. (Pubitemid 39099767)
9. Heist RS, Zhou W, Chirieac LR, et al.: MDM2 polymorphism, survival, and histology in early-stage non-small cell lung cancer. J Clin Oncol 2007; 25: 2243-2247. (Pubitemid 46954650)
10. Heist RS, Zhai R, Liu G, et al.: VEGF polymorphisms and survival in early-stage non-small cell lung cancer. J Clin Oncol 2008; 26: 856-862. (Pubitemid 351398076)
11. Yoo SS, Choi JE, Lee WK, et al.: Polymorphisms in the Caspase genes and survival in patients with early-stage non-small-cell lung cancer. J Clin Oncol 2009; 27: 5823-5829.
12. Lee EB, Jheon HS, Yoo SS, et al.: Polymorphisms in the apoptosis-related genes and survival of patients with early stage non-small cell lung cancer. Ann Surg Oncol 2010; 17: 2608-2618.
13. Vivanco I, Sawyers CL,: The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501. (Pubitemid 37328931)
14. Luo J, Manning BD, Cantley LC,: Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 2003; 4: 257-262. (Pubitemid 37329790)
15. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR,: Activation of AKT kinase in cancer: Implications for therapeutic targetings. Adv Cancer Res 2005; 94: 29-86. (Pubitemid 41202364)
16. Brognard J, Clark AS, Ni Y, Dennis PA,: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-3997. (Pubitemid 32720961)
17. Malanga D, Scrima M, De Marco C, et al.: Activating E17K mutation in the gene coding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008; 7: 665-669. (Pubitemid 351499006)
18. Emamian ES, Hall D, Birnbaum MJ, et al.: Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat Genet 2004; 36: 131-137. (Pubitemid 38174370)
19. Harris SL, Gil G, Robins H, et al.: Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci USA 2005; 102: 16297-16302. (Pubitemid 41688908)
20. Detterbeck FC, Boffa DJ, Tanoue LT,: The new lung cancer staging system. Chest 2009; 136: 260-271.
21. Barrett JC, Fry B, Maller J, Daly MJ,: Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
22. Gabriel SB, Schaffner SF, Nguyen H, et al.: The structure of haplotype blocks in the human genome. Science, 2002; 296: 2225-2229. (Pubitemid 34680308)
23. Stephens M, Smith MJ, Donnelly P,: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989. (Pubitemid 32289743)
24. Zai CC, Romano-Silva MA, Hwang R, et al.: Genteic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophr Res 2008; 106: 248-252.
25. Schwab SG, Hoefgen B, Hanses C, et al.: Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Pshychiatry 2005; 58: 446-450. (Pubitemid 41393606)
26. Ide M, Ohnishi T, Muray M, et al.: Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia. J Neurochem 2006; 99: 277-287. (Pubitemid 44395150)
27. Ikeda M, Iwata N, Suzuki T, et al.: Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol Psychiatry 2004; 56: 698-700. (Pubitemid 39446853)
28. Xu MQ, Xing QH, Zheng YL, et al.: Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry 2007; 68: 1358-1367.
29. Datta SR, Brunet A, Greenberg ME,: Cellular survival: A play in three Akts. Genes Dev 1999; 13: 2905-2927.
30. Dimmeler S, Fleming I, Fisslthaler B, et al.: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605.
31. Grille SJ, Bellacosa A, Upson J, et al.: The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003; 63: 2172-2178. (Pubitemid 36538623)
32. Shah A, Swain WA, Richardson D, et al.: Phospho-Akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 2930-2936. (Pubitemid 40525195)
33. Lim WT, Zhang WH, Miller CR, et al.: PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep 2007; 17: 853-857.
34. Lotkionov A,: Common gene polymorphisms, cancer progression and prognosis. Cancer Lett 2004; 208: 1-33.
35. Sekido Y, Fong KM, Minna JD,: Molecular genetics of lung cancer. Annu Rev Med 2003; 54: 73-87. (Pubitemid 37386386)
36. Bhattacharjee A, Richards WG, Staunton J, et al.: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790-13795. (Pubitemid 33115977)
37. Sun Z, Yang P,: Gene expression profiling on lung cancer outcome prediction: Present clinical value and future premise. Cancer Epidemiol Biomark Prev 2006; 15: 2063-2068. (Pubitemid 44877027)